吉林秉责律师事务所 关于通化东宝药业股份有限公司 二 0 二五年第一次临时股东会的法律意见书 致：通化东宝药业股份有限公司 根据《中华人民共和国证券法》（以下简称"证券法"）、《中华人民共和国 公司法》（以下简称《公司法》）、《上市公司股东会规则》（以下简称《股东会规 则》）和《通化东宝药业股份有限公司章程》（以下简称《公司章程》）的有关规 定，吉林秉责律师事务所（以下简称"本所"）接受了通化东宝药业股份有限公 司（以下简称"公司"）的委托，担任公司 2025 年第一次临时股东会（以下简称 "本次股东会"）特聘专项法律顾问并出具法律意见书。 本法律意见书仅供公司为本次股东会之目的而使用，不得用于其他任何目 的。本所同意公司将本法律意见书作为本次股东会的公告材料，随其他需要公告 的信息一起向公众披露，并依法对本所在其中发表的法律意见承担责任。 为出具本法律意见书，本所指派郭淑芬、商家碧律师出席了公司于 2025 年 6 月 9 日上午 10 时在公司会议室召开的本次股东会，审查了公司提供的与召开 本次股东会有关的文件和资料，并进行了验证。在此基础上，本所按照律师行业 公认的业务标准、道德规范和勤勉尽责的精神发表 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-040 重要内容提示: 通化东宝药业股份有限公司（以下简称"公司"或"本公司"）控股股东东 宝实业集团股份有限公司（以下简称"东宝集团"）及其一致行动人合计持有公 司股份 623,593,436 股，占公司目前股份总额的 31.84%；东宝集团及其一致行 动人持有公司股份累计质押数量（本次解押及再质押后）为 565,939,472 股，占 其及一致行动人所持有公司股份总额的 90.75%，占公司目前股份总额的 28.90%。 其中：东宝集团持有公司股份 601,731,257 股，占公司目前股份总额的 30.72%， 东宝集团持有公司股份累计质押数量（本次解押及再质押后）为 565,939,472 股， 占其所持有公司股份总额的 94.05%，占公司目前股份总额的 28.90%。 2025 年 5 月 29 日,本公司接到东宝集团关于股份解押及再质押相关情况的 告知函,具体情况如下: 一、公司控股股东本次股份质押解除的具体情况 通化东宝药业股份有限公司 关于控股股东股份解押及再质押公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 ...

Industry Investment Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The ASCO conference has showcased significant data from several domestic innovative drugs, highlighting opportunities for innovation and performance resonance [1][4] - The report emphasizes the increasing competitiveness and international influence of Chinese pharmaceutical companies, with a record number of original research results presented at ASCO [4][5] - The report suggests a positive outlook for the innovative drug sector, driven by favorable policies and low valuations compared to historical averages [4] Summary by Sections Market Performance - The Hang Seng Index fell by 2.4% during the week, while the Hang Seng Healthcare Index decreased by 1.0%, ranking 7th among 12 industry indices [4][22] - Sub-industry performance varied, with life sciences tools and services up by 3.4%, and biotechnology down by 4.9% [4][22] Company Ratings and Valuations - The report provides a detailed valuation summary for various companies, with most rated as "Buy" and a few as "Neutral" or "Sell" [3][42] - Notable companies with "Buy" ratings include: - AstraZeneca (AZN US) with a target price of 93.30 and a current price of 70.96 [3] - BeiGene (6160 HK) with a target price of 208.80 and a current price of 146.00 [3] - Innovent Biologics (1801 HK) with a target price of 60.00 and a current price of 59.55 [3] ASCO Conference Highlights - The 2025 ASCO conference featured 71 original research results from Chinese pharmaceutical companies, with 11 studies presented as Late Breaking Abstracts [5][6] - Companies like Innovent Biologics and Rongchang Biologics showcased promising clinical data for their innovative therapies [5][6] Investment Recommendations - The report recommends focusing on companies with strong growth potential and clear profitability timelines, such as Rongchang Biologics, Kangfang Biologics, and Innovent Biologics [4] - It also highlights the potential for prescription drug companies like Xiansheng Pharmaceutical and Hansoh Pharmaceutical to expand their valuations due to high growth rates [4] Recent Approvals and Developments - Rongchang Biologics received approval for a new indication for its drug in treating myasthenia gravis [20] - Innovent Biologics published positive results for its dual receptor agonist in a prominent medical journal [20] - BeiGene's clinical research for its drug in small cell lung cancer has shown promising results [20]

通化东宝药业股份有限公司 关于控股股东股份解押及再质押公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 证券代码：600867 证券简称：通化东宝 公告编号：2025-039 通化东宝药业股份有限公司（以下简称"公司"或"本公司"）控股股东东 宝实业集团股份有限公司（以下简称"东宝集团"）及其一致行动人合计持有公 司股份 623,593,436 股，占公司目前股份总额的 31.84%；东宝集团及其一致行 动人持有公司股份累计质押数量（本次解押及再质押后）为 557,439,472 股，占 其及一致行动人所持有公司股份总额的 89.39%，占公司目前股份总额的 28.46%。 其中：东宝集团持有公司股份 601,731,257 股，占公司目前股份总额的 30.72%， 东宝集团持有公司股份累计质押数量（本次解押及再质押后）为 557,439,472 股， 占其所持有公司股份总额的 92.64%，占公司目前股份总额的 28.46%。 2025 年 5 月 28 日,本公司接到东宝集团关于股份解押及再质押相关情况 ...

通化东宝药业股份有限公司 2025 年第一次临时股东会会议资料 股票简称：通化东宝 股票代码：600867 二〇二五年六月九日 通化东宝药业股份有限公司 2025 年第一次临时股东会会议资料 目 录 | 2025 | 年第一次临时股东会会议议程 | 3 | | --- | --- | --- | | 议案 | 1：关于协议转让特宝生物部分股份的议案 | 4 | 2 通化东宝药业股份有限公司 2025 年第一次临时股东会会议资料 2025 年第一次临时股东会 会议议程 一、会议时间： 现场会议时间：2025 年 6 月 9 日上午 10 时 网络投票时间：网络投票起止时间：自 2025 年 6 月 9 日 至 2025 年 6 月 9 日 采用上海证券交易所网络投票系统，通过上海证券交易所交易系统进行网络 投 票 时 间 为 股 东 会 召 开 当 日 的 交 易 时 间 段 ， 即 9:15-9:25,9:30-11:30 ， 13:00-15:00；通过互联网投票平台的投票时间为股东会召开当日的 9:15-15:00。 二、会议召开地点：公司会议室 三、会议议程： （一）主持人宣布会议开始 （二）推选股东会 ...

Group 1 - The company is actively expanding its international market presence, particularly in the U.S. insulin market through strategic partnerships and ongoing clinical trials for three types of insulin [1] - The company has achieved sales of approximately 200,000 units of liraglutide injection in Q1 2025, with a strong foundation for annual sales growth due to successful procurement results [2] - The company is focusing on the sales of insulin analog products and expanding its market presence for GLP-1 receptor agonists and SGLT-2 inhibitors to meet diverse patient needs [2] Group 2 - The company has received approvals for insulin products in several developing countries, including Nicaragua and Uzbekistan, and is working on expanding registrations for insulin products in these markets [1] - The company is advancing its clinical trials for new products, including THDBH120 for weight loss, which has completed its Phase II clinical trial [2][3] - The company is not currently developing oral insulin products due to technical challenges but will monitor industry advancements for potential future adjustments in R&D strategy [3] Group 3 - The company’s parent group, Dongbao Group, is working to reduce its share pledge ratio, which is currently high due to long project cycles and financial pressures [3] - The long-term outlook for Dongbao Group is positive, with ongoing projects and products expected to enter a recovery phase, improving operational capabilities [4]

Core Viewpoint - Tonghua Dongbao is undergoing a financial crisis and is liquidating assets by reducing its stake in TEBIO to raise funds for innovative drug development, amidst declining profits and increasing operational costs [1][2][16]. Financial Performance - In Q1 2024, Tonghua Dongbao reported a net profit decline of over 49%, marking the first annual loss in its history [2][19]. - The company's revenue for 2024 is projected to be 20.10 billion yuan, a decrease of 34.66% year-on-year, with a net loss of 0.43 billion yuan [16][18]. - The gross margin for insulin products has decreased, while sales and management expenses have risen, contributing to the decline in performance [3][19]. Asset Liquidation - The company plans to transfer 5.70% of its stake in TEBIO for approximately 13 billion yuan, which is about 20% lower than the market price [6][7][8]. - This transfer is part of a series of asset liquidations, with previous sales totaling around 12.80 billion yuan, reducing its stake in TEBIO to 16.03% [12][13][14]. Debt and Financial Pressure - As of Q1 2024, Tonghua Dongbao has 688 million yuan in cash and 790 million yuan in interest-bearing debt, indicating a tight liquidity position [4][8]. - The major shareholder, Dongbao Industrial Group, has a high equity pledge rate of 91.64%, reflecting its financial strain [4][23]. Market Position and Future Outlook - Despite the current challenges, Tonghua Dongbao remains a leading player in the domestic insulin market, with a history of strong performance [16]. - The company has secured a significant share of the national insulin procurement, but profit margins are expected to remain under pressure due to price reductions [18][19].

Group 1 - The core point of the news is that Tonghua Dongbao plans to transfer 23.1876 million shares of Tebao Bio, reducing its stake from 16.03% to 10.33% after the transfer, which amounts to a total transaction value of 1.301 billion yuan at a price of 56.12 yuan per share [1] - Tonghua Dongbao has been a long-term partner of Tebao Bio since its establishment in 2000 and has gradually reduced its stake since the lifting of share restrictions, realizing investment returns [1][2] - The share transfer is part of Tonghua Dongbao's strategy to enhance its innovation-driven transformation and improve asset utilization, which is expected to significantly boost its net profit and earnings per share in the second quarter [2] Group 2 - Tebao Bio's stock price increased by 6.31% in the first quarter, with a current market value of 30.3 billion yuan, and it has entered the top ten heavy stocks of 32 funds [2] - Tebao Bio's revenue has grown from 794 million yuan in 2020 to 2.817 billion yuan in 2024, while net profit increased from 117 million yuan to 828 million yuan during the same period [2] - Tonghua Dongbao's recent financial struggles are attributed to a new round of insulin procurement that began last year, leading to a decline in sales and profits, with a projected revenue of 2.009 billion yuan for 2024, a decrease of 34.66% year-on-year [3]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 8.00 CNY based on a 25x PE valuation for 2025 [2][5]. Core Insights - The impact of centralized procurement is gradually clearing, and the company's innovative pipeline is progressing smoothly [1]. - The company has adjusted its revenue and gross margin expectations downward due to the effects of centralized procurement, while overall expense ratios have been adjusted upward [2]. - The company reported a significant decline in revenue and net profit for 2024, primarily due to the implementation of a new round of insulin centralized procurement and inventory control by commercial clients [10]. - Despite the challenges, overseas revenue showed strong growth, with a nearly 80% year-on-year increase in the first quarter of 2025 [10]. - The company is making progress in its research and development pipeline, with positive results from clinical trials for several products [10]. Financial Information Summary - **Revenue Forecast**: The company expects revenues of 2,708 million CNY in 2025, up from 2,010 million CNY in 2024, reflecting a growth rate of 34.7% [4]. - **Net Profit Forecast**: The forecasted net profit for 2025 is 630 million CNY, a significant recovery from a loss of 43 million CNY in 2024 [4]. - **Earnings Per Share**: The expected earnings per share for 2025 is 0.32 CNY, with projections of 0.40 CNY and 0.47 CNY for 2026 and 2027, respectively [4]. - **Gross Margin**: The gross margin is projected to decline slightly from 73.9% in 2024 to 71.8% in 2025 [4]. - **Net Margin**: The net margin is expected to recover to 23.3% in 2025 from a negative margin in 2024 [4].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 8.00 CNY based on a 25x PE valuation for 2025 [2][5]. Core Views - The impact of centralized procurement is gradually clearing, and the progress of the innovation pipeline is smooth [1]. - The company has adjusted its revenue and gross margin expectations downward due to the effects of centralized procurement, while overall expense ratios have been adjusted upward [2]. - The company is expected to recover in revenue in 2025, with projected earnings per share of 0.32 CNY, 0.40 CNY, and 0.47 CNY for 2025, 2026, and 2027 respectively [2]. Financial Information Summary - **Revenue Forecast**: The company is projected to generate revenues of 2,708 million CNY in 2025, 3,216 million CNY in 2026, and 3,546 million CNY in 2027, reflecting a growth of 34.7%, 18.8%, and 10.3% respectively [4]. - **Net Profit**: The forecasted net profit attributable to the parent company is expected to be 630 million CNY in 2025, 788 million CNY in 2026, and 911 million CNY in 2027, showing significant growth of 1575.4% in 2025 [4]. - **Gross Margin**: The gross margin is projected to decline from 80.1% in 2023 to 71.3% in 2027 [4]. - **Earnings Per Share**: The earnings per share are expected to recover from a loss of 0.02 CNY in 2024 to 0.32 CNY in 2025, 0.40 CNY in 2026, and 0.47 CNY in 2027 [4]. Market Performance - The company's stock price was 7.67 CNY as of May 21, 2025, with a 52-week high of 9.8 CNY and a low of 7 CNY [5]. - The company has shown a relative performance of 2.67% over the past month compared to the CSI 300 index [6].